Financial benefits, faster approvals and less stringent clinical data requirements are some important benefits that regulatory agencies across the world offer as incentives for development of orphan drugs for rare diseases. These countries include the US, Europe, Japan, Australia, South Korea, Brazil and most recently, India. These incentives have been so supportive and convincingly helpful […]

Read More →

Trial managers worldwide have been focusing on specific regions for placing their clinical trials. So much so that about 60-70% of clinical trials globally are conducted in USA and Europe alone. However, this is slated to change or should change, if one consults a recent white paper published by Frost & Sullivan. The white paper […]

Read More →